Overview

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Status:
Completed
Trial end date:
2020-02-21
Target enrollment:
Participant gender:
Summary
Objective of this study is to investigate the efficacy, safety and pharmacokinetics of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.
Phase:
Phase 2
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Treatments:
Pramipexole